Internal Medicine V, Hematology and Oncology, Medical University Innsbruck, Anichstraße 35, A- 6020, Innsbruck, Austria; Tiroler Krebsforschung Institut (TKFI), Innrain 66, A-6020, Innsbruck, Austria.
Internal Medicine V, Hematology and Oncology, Medical University Innsbruck, Anichstraße 35, A- 6020, Innsbruck, Austria.
Crit Rev Oncol Hematol. 2020 Sep;153:102948. doi: 10.1016/j.critrevonc.2020.102948. Epub 2020 May 5.
In the highly dynamic field of advanced malignancies, biomarkers from liquid samples are urgently needed to improve treatment tailoring. However, the heterogenic data lack direct comparison of assays, vectors and relevant validations are rarely found. Therefore, we classified the available studies based on three categories: Measured vectors, applied technique and detected biomarker. High blood tumor mutational burden and low baseline levels of soluble programmed cell death 1 ligand 1 (PD-L1) appear to predict treatment responses to immunotherapy. A high PD-1 CD4 T-cell count was associated with poor overall survival, PD-1CD8 T-cells connect to a favorable outcome. Circulating tumor cells expressing PD-L1 were mainly associated with poor overall survival and treatment failure. CONCLUSION: Measurement of immunological factors as liquid biomarkers is feasible and has shown promising results. The use of coherent nomenclatures, cross-platform assay comparisons and validations through appropriate powered clinical trials are urgently required to push this auspicious field.
在高度动态的晚期恶性肿瘤领域，迫切需要从液体样本中获取生物标志物，以改善治疗的针对性。然而，异质数据缺乏对检测方法的直接比较，并且很少有相关的验证。因此，我们根据三个类别对现有研究进行了分类：测量载体、应用技术和检测生物标志物。高血液肿瘤突变负担和低基线水平的可溶性程序性死亡配体 1（PD-L1）似乎可预测免疫治疗的反应。高 PD-1 CD4 T 细胞计数与总生存期不良相关，PD-1 CD8 T 细胞与良好的结果相关。表达 PD-L1 的循环肿瘤细胞主要与总生存期不良和治疗失败相关。结论：作为液体生物标志物的免疫因子的测量是可行的，并且已经显示出有希望的结果。迫切需要使用一致的命名法、跨平台检测方法比较以及通过适当的大型临床试验进行验证，以推动这一有前途的领域发展。
